Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1974 1
1975 1
1977 2
1978 1
1980 1
1981 1
1983 1
1985 1
1990 1
1991 1
1992 1
1995 1
1996 1
1998 1
2002 2
2003 3
2004 4
2005 1
2006 1
2007 1
2010 1
2011 1
2013 4
2014 1
2015 5
2016 9
2017 1
2019 4
2020 8
2021 12
2022 14
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Stevens RM, Campbell JN, Hanson PD. Stevens RM, et al. Arthritis Rheumatol. 2020 Aug;72(8):1405-1406. doi: 10.1002/art.41287. Epub 2020 May 31. Arthritis Rheumatol. 2020. PMID: 32301590 No abstract available.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. Among authors: stevens rm. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Paul C, et al. Among authors: stevens rm. Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7. Br J Dermatol. 2015. PMID: 26357944 Clinical Trial.
Metastatic Wilms tumor and dilated cardiomyopathy.
Mohan V, Kilcoyne MF, Stevens RM, Mahan VL. Mohan V, et al. Among authors: stevens rm. Ann Pediatr Cardiol. 2021 Oct-Dec;14(4):564-565. doi: 10.4103/apc.apc_272_20. Epub 2022 Mar 25. Ann Pediatr Cardiol. 2021. PMID: 35527769 Free PMC article. No abstract available.
Etiology of problem gambling in Canada.
Williams RJ, Shaw CA, Belanger YD, Christensen DR, El-Guebaly N, Hodgins DC, McGrath DS, Stevens RMG. Williams RJ, et al. Among authors: stevens rmg. Psychol Addict Behav. 2023 May;37(3):483-498. doi: 10.1037/adb0000843. Epub 2022 Jul 4. Psychol Addict Behav. 2023. PMID: 35787101
Indigenous Gambling and Problem Gambling in Canada.
Williams RJ, Belanger YD, Leonard CA, Stevens RMG, Christensen DR, El-Guebaly N, Hodgins DC, McGrath DS. Williams RJ, et al. Among authors: stevens rmg. J Gambl Stud. 2022 Mar;38(1):67-85. doi: 10.1007/s10899-021-10022-5. Epub 2021 Mar 17. J Gambl Stud. 2022. PMID: 33733295
Chronic fluorosis.
Stevens RM. Stevens RM. Br Med J (Clin Res Ed). 1981 Feb 28;282(6265):741-2. doi: 10.1136/bmj.282.6265.741-d. Br Med J (Clin Res Ed). 1981. PMID: 6781646 Free PMC article. No abstract available.
87 results